ArticleCancers2021
Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0.Journal for immunotherapy of cancer · 2023Guideline
- Body Mass Index and Body Fat Percentage Are Associated with Clinical Outcomes in Patients Receiving PD-1/PD-L1 Inhibitors: A Prospective Exploratory Study.Journal of personalized medicine · 2026Article
- Risk modifiers of immune-related adverse events in patients with NSCLC undergoing immunotherapy: a retrospective cohort study.Journal of pharmaceutical health care and sciences · 2026Article
- Risk factors for immune checkpoint inhibitor colitis: a retrospective multi-center cohort study using electronic health records.Cancer immunology, immunotherapy : CII · 2026Article
- Demographic Variations in Immune Checkpoint Inhibitor Adverse Events: A Real-World Study.World journal of oncology · 2025Article
- Rate of response to immune checkpoint inhibitor therapy in patients with conjunctival melanoma.Melanoma research · 2025Article
- Osteoarthritis increases the risk of inflammatory arthritis due to immune checkpoint inhibitors associated with tissue-resident memory T cells.Journal for immunotherapy of cancer · 2025Article
- Immune checkpoint inhibitor-induced toxicity: a real-world analysis of the role of BMI.Frontiers in oncology · 2025Article
- The multifactorial effect of obesity on the effectiveness and outcomes of cancer therapies.Nature reviews. Endocrinology · 2024Review
- Article
- Review
- Clinical Outcomes of Immune Checkpoint Inhibitors in Unique Cohorts Underrepresented in Clinical Trials.Cancers · 2024Article
- Article
- Risk factors indicating immune-related adverse events with combination chemotherapy with immune checkpoint inhibitors and platinum agents in patients with non-small cell lung cancer: a multicenter retrospective study.Cancer immunology, immunotherapy : CII · 2023Article
- Multi-omics analysis of DNA replication-associated primase polymerase (PRIMPOL) in pan-cancer: a potential target for prognosis and immune response.European journal of medical research · 2023Article
- Article
- Article
- Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer.Expert review of anticancer therapy · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
Abstract
Evidence regarding the association between body mass index (BMI) and immune-related adverse events (irAEs) among cancer patients receiving immune checkpoint inhibitors (ICIs) is limited. Here, we use cross-sectional hospital-based data to explore their relationship. Pre-treatment BMI was treated as an ordinal variable (<25, 25 to ≤30, ≥30 kg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.